Amarin Corp Plcuk (AMRN) Non-Current Debt (2010 - 2019)
Amarin Corp Plcuk (AMRN) posted quarterly Non-Current Debt of $8.9 million for Q3 2019, down 69.55% YoY from $29.2 million in Q3 2018, and down 61.74% sequentially from $23.2 million in Q2 2019.
Amarin Corp Plcuk (AMRN) Non-Current Debt (2010 - 2019) Analysis & Trends
Amarin Corp Plcuk has disclosed Non-Current Debt across 10 years of filings, most recently posting $8.9 million for Q3 2019.
- In Q3 2019, Non-Current Debt fell 69.55% year-over-year to $8.9 million; the TTM figure through Sep 2019 stood at $8.9 million (down 69.55% YoY), while the FY2018 annual figure was $46.1 million, up 59.04% from the prior year.
- Non-Current Debt slipped to $8.9 million in Q3 2019, from $23.2 million in the prior quarter.
- Over the last five years, Non-Current Debt for AMRN reached as high as $136.7 million in Q4 2015 and fell as low as $8.9 million in Q3 2019.
- The 5-year median for Non-Current Debt is $62.7 million (2017), against an average of $64.7 million.
- Annual changes were most pronounced in 2018 — Non-Current Debt jumped 59.04% — and 2019, when it sank 69.55%.
- A 5-year view of Non-Current Debt shows it stood at $136.7 million in 2015, then plunged by 37.72% to $85.2 million in 2016, then slumped by 65.95% to $29.0 million in 2017, then jumped by 59.04% to $46.1 million in 2018, then slumped by 80.75% to $8.9 million in 2019.
- According to Business Quant data, Non-Current Debt over the past three periods registered $8.9 million, $23.2 million, and $35.3 million for Q3 2019, Q2 2019, and Q1 2019 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 39.37 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 37.53 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 64.53 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -24.45 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 46.67 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 51.89 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 20.86 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 60.57 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Amarin Corp Plcuk | 5.17 Bn | 5.00 Bn | 17.77 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | 8.88 Mn |
| Jun 30, 2019 | 23.20 Mn |
| Mar 31, 2019 | 35.34 Mn |
| Dec 31, 2018 | 46.11 Mn |
| Sep 30, 2018 | 29.16 Mn |
| Jun 30, 2018 | 29.10 Mn |
| Mar 31, 2018 | 29.05 Mn |
| Dec 31, 2017 | 28.99 Mn |
| Sep 30, 2017 | 28.94 Mn |
| Jun 30, 2017 | 79.28 Mn |
| Mar 31, 2017 | 82.41 Mn |
| Dec 31, 2016 | 85.16 Mn |
| Jun 30, 2016 | 125.64 Mn |
| Mar 31, 2016 | 92.02 Mn |
| Dec 31, 2015 | 136.73 Mn |
| Sep 30, 2015 | 91.01 Mn |
| Jun 30, 2015 | 90.52 Mn |
| Mar 31, 2015 | 123.19 Mn |
| Dec 31, 2014 | 121.85 Mn |
| Sep 30, 2014 | 120.49 Mn |